Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
7 Highly Liquid Insider Stock Picks Reporting Earnings Next WeekKapitall • Thu, Jul 26, 2012
-
-
-
Vical's CEO Discusses Q3 2012 Results - Earnings Call TranscriptWed, Nov 7, 2012
-
Vical's CEO Discusses Q2 2012 Results - Earnings Call TranscriptWed, Aug 1, 2012
-
Vical's CEO Discusses Q1 2012 Results - Earnings Call TranscriptWed, May 2, 2012
-
Vical's CEO Discusses Q4 2011 Results - Earnings Call TranscriptWed, Feb 8, 2012
-
Vical's CEO Discusses Q2 2011 Results - Earnings Call TranscriptWed, Aug 3, 2011 • 2 Comments
-
Vical's CEO Discusses Q1 2011 Results - Earnings Call TranscriptThu, May 5, 2011
-
Vical CEO Discusses Q4 2010 Results - Earnings Call TranscriptThu, Feb 10, 2011
-
Vical Analyst and Investor Day TranscriptWed, Nov 10, 2010
-
Vical Incorporated. Q2 2010 Earnings Call TranscriptTue, Aug 3, 2010 • 1 Comment
-
Vical Incorporated Q1 2010 Earnings Call TranscriptFri, May 7, 2010
-
Vical, Inc. Q4 2009 Earnings Call TranscriptFri, Feb 12, 2010
-
GlobeNewswire (Wed, 6:30AM)
-
GlobeNewswire (May 23, 2013)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 7, 2013)
-
GlobeNewswire (May 6, 2013)
-
GlobeNewswire (May 2, 2013)
-
GlobeNewswire (Apr 22, 2013)
-
GlobeNewswire (Feb 27, 2013)
-
GlobeNewswire (Feb 6, 2013)
-
GlobeNewswire (Feb 5, 2013)
-
GlobeNewswire (Feb 4, 2013)
-
GlobeNewswire (Jan 30, 2013)
-
at CNBC.com (Jan 9, 2013)
-
GlobeNewswire (Jan 3, 2013)
-
GlobeNewswire (Jan 2, 2013)
-
GlobeNewswire (Dec 5, 2012)
-
GlobeNewswire (Nov 12, 2012)
-
GlobeNewswire (Nov 8, 2012)
-
GlobeNewswire (Nov 7, 2012)
-
GlobeNewswire (Nov 2, 2012)
VICL vs. ETF Alternatives
Company Description
We research and develop biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. We believe the following areas of research offer the greatest potential for near-term commercialization for us and our... More
